JP2009502971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502971A5 JP2009502971A5 JP2008524273A JP2008524273A JP2009502971A5 JP 2009502971 A5 JP2009502971 A5 JP 2009502971A5 JP 2008524273 A JP2008524273 A JP 2008524273A JP 2008524273 A JP2008524273 A JP 2008524273A JP 2009502971 A5 JP2009502971 A5 JP 2009502971A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aralkyl
- compound
- formula
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- -1 mechloretamine Chemical compound 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 238000000746 purification Methods 0.000 claims 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- 239000002002 slurry Substances 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052711 selenium Inorganic materials 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 108010049048 Cholera Toxin Proteins 0.000 claims 2
- 102000009016 Cholera Toxin Human genes 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 229930192392 Mitomycin Natural products 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 108010081690 Pertussis Toxin Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 238000002844 melting Methods 0.000 claims 2
- 230000008018 melting Effects 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 229940086322 navelbine Drugs 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000000813 small intestine Anatomy 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 claims 1
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 claims 1
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000006491 bone marrow cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 claims 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70416305P | 2005-07-29 | 2005-07-29 | |
| US60/704,163 | 2005-07-29 | ||
| PCT/US2006/029835 WO2007027344A2 (en) | 2005-07-29 | 2006-07-28 | Compounds and methods for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502971A JP2009502971A (ja) | 2009-01-29 |
| JP2009502971A5 true JP2009502971A5 (enExample) | 2011-09-22 |
| JP4994374B2 JP4994374B2 (ja) | 2012-08-08 |
Family
ID=37809342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524273A Active JP4994374B2 (ja) | 2005-07-29 | 2006-07-28 | がんを治療するための化合物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7968738B2 (enExample) |
| EP (2) | EP2394702B1 (enExample) |
| JP (1) | JP4994374B2 (enExample) |
| AU (1) | AU2006285329B2 (enExample) |
| CA (1) | CA2617049A1 (enExample) |
| ES (2) | ES2532666T3 (enExample) |
| NO (1) | NO20081045L (enExample) |
| WO (1) | WO2007027344A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2394702B1 (en) | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| US8252773B2 (en) * | 2007-11-02 | 2012-08-28 | Ziopharm Oncology, Inc. | Combination therapy with organic arsenicals |
| WO2009075870A1 (en) * | 2007-12-12 | 2009-06-18 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| NZ591181A (en) * | 2008-08-20 | 2012-09-28 | Ziopharm Oncology Inc | Organoarsenic compounds and methods for the treatment of cancer |
| CN104768875A (zh) | 2012-09-20 | 2015-07-08 | 于伽·纳拉扬·本德勒 | 纳米三氧化二砷的生物合成方法及其在治疗包括癌症的疾病中的用途 |
| US20160304546A1 (en) * | 2013-12-05 | 2016-10-20 | Solasia Pharma K.K. | Compounds and methods for the treatment of cancer |
| CN107530476A (zh) * | 2015-03-12 | 2018-01-02 | 般财团法人化学及血清疗法研究所 | 使用脱细胞化组织的抗粘连材料和代用生物膜 |
| CN107167433A (zh) * | 2016-03-07 | 2017-09-15 | 天津国际生物医药联合研究院 | 一种检测氯二甲基砷的方法 |
| WO2019220961A1 (ja) * | 2018-05-18 | 2019-11-21 | ソレイジア・ファーマ株式会社 | ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| DE69840057D1 (de) | 1997-10-15 | 2008-11-06 | Polarx Biopharmaceuticals Inc | Pharmazeutische Zusammensetzungen enthaltend Arsentrioxid zur Behandlung von Krebs des zentralen Nervensystems |
| EP1964557B1 (en) | 1997-11-10 | 2013-01-02 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations |
| WO1999029336A1 (en) * | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| SE9802080D0 (sv) * | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| US7022315B2 (en) | 2000-04-26 | 2006-04-04 | Oregon Health & Science University | Administration of a thiol-based chemoprotectant compound |
| EP2420229A1 (en) * | 2002-01-07 | 2012-02-22 | Board Of Regents, University Of Texas System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| TW201440760A (zh) * | 2004-07-16 | 2014-11-01 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| EP2394702B1 (en) | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| US8252773B2 (en) * | 2007-11-02 | 2012-08-28 | Ziopharm Oncology, Inc. | Combination therapy with organic arsenicals |
-
2006
- 2006-07-28 EP EP11180330.0A patent/EP2394702B1/en not_active Not-in-force
- 2006-07-28 ES ES11180330.0T patent/ES2532666T3/es active Active
- 2006-07-28 EP EP06824793.1A patent/EP1919564B1/en active Active
- 2006-07-28 US US11/495,172 patent/US7968738B2/en active Active
- 2006-07-28 AU AU2006285329A patent/AU2006285329B2/en not_active Ceased
- 2006-07-28 WO PCT/US2006/029835 patent/WO2007027344A2/en not_active Ceased
- 2006-07-28 JP JP2008524273A patent/JP4994374B2/ja active Active
- 2006-07-28 ES ES06824793T patent/ES2531159T3/es active Active
- 2006-07-28 CA CA002617049A patent/CA2617049A1/en not_active Abandoned
-
2008
- 2008-02-28 NO NO20081045A patent/NO20081045L/no not_active Application Discontinuation
-
2011
- 2011-06-01 US US13/150,516 patent/US8334398B2/en active Active
-
2012
- 2012-11-14 US US13/676,929 patent/US8865764B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502971A5 (enExample) | ||
| JP2005527487A5 (enExample) | ||
| JP6315841B2 (ja) | 有機ヒ素化合物および癌を処置するための方法 | |
| RU2140422C1 (ru) | Трехплатиновые комплексы pt(ii), способ их получения | |
| CA2435653A1 (en) | Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium | |
| ES2532666T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| AU2004292933B2 (en) | Targeting of Erb antigens | |
| CN101395166B (zh) | 用于治疗癌症的化合物和方法 | |
| JP2019514969A (ja) | 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬 | |
| Pazderová et al. | Complexes of cyclen side-bridged with a methylene-bis (phosphinate) group | |
| WO2008155727A1 (en) | Platinum (iv) complexes | |
| JP2016540775A5 (enExample) | ||
| JP2009527463A5 (enExample) | ||
| TWI617305B (zh) | 治療癌症的化合物及其應用程序 | |
| AU776071B2 (en) | Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents | |
| WO2006138357A1 (en) | Macrocyclic metal complexes for their use as anticancer agents | |
| Kohorn | Uracil Mustard and 5-Fluorouracil Combination Chemotherapy: A Historic Record. | |
| CN101289421A (zh) | 烟酰氨基酸类化合物的合成方法及其对肿瘤放疗的增敏作用 | |
| CN101511801A (zh) | 三嗪衍生化合物和包含该化合物的用于治疗癌症的组合物 | |
| EP4355753A1 (en) | Complexes of cu(i) as antitumor agents | |
| Durmus | Silver (I) and Gold (I) N-Heterocyclic Carbene Complexes | |
| CN117899224A (zh) | 一种抗肿瘤的联用组合药物及其应用 | |
| CN107434822A (zh) | 博来霉素衍生物及制备方法和应用 | |
| Koteswara Rao et al. | Adenin-1-ium hydrogen isophthalate dimethylformamide monosolvate | |
| CN107434821A (zh) | 一种111铟‑博来霉素衍生物的螯合物及应用 |